LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Home・Elenco Azioni・Compugen Ltd

Compugen Ltd

Chiusa

2.03 -2.87

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

Massimo

2.12

Metriche Chiave
By Trading Economics
Entrata	-65M -7.7M
Vendite	-65M 2.2M
P/E Media del settore	6.474 49.888
EPS	-0.08
Margine di Profitto	-352.436
Dipendenti	75
EBITDA	-64M -7.7M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+138.1% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-38M 233M
Apertura precedente	4.9
Chiusura precedente	2.03

Compugen Ltd Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 giu 2026, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 giu 2026, 15:41 UTC

I principali Market Mover

American Battery Shares Jump on Energy Department Victory

8 giu 2026, 23:46 UTC

Discorsi di Mercato

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 giu 2026, 23:37 UTC

Discorsi di Mercato

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 giu 2026, 23:25 UTC

Discorsi di Mercato

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 giu 2026, 23:25 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 giu 2026, 21:57 UTC

Acquisizioni, Fusioni, Takeovers

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 giu 2026, 21:56 UTC

Acquisizioni, Fusioni, Takeovers

Salesforce Agrees to Buy m3ter

8 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

8 giu 2026, 19:22 UTC

Discorsi di Mercato

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 giu 2026, 19:01 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 giu 2026, 18:52 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

8 giu 2026, 18:52 UTC

Discorsi di Mercato

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 giu 2026, 18:17 UTC

Discorsi di Mercato

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 giu 2026, 17:32 UTC

Discorsi di Mercato

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 giu 2026, 17:29 UTC

Discorsi di Mercato

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 giu 2026, 17:29 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

8 giu 2026, 16:55 UTC

Acquisizioni, Fusioni, Takeovers

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 giu 2026, 16:54 UTC

Acquisizioni, Fusioni, Takeovers

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 giu 2026, 16:40 UTC

Discorsi di Mercato

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 giu 2026, 16:31 UTC

Discorsi di Mercato

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 giu 2026, 16:27 UTC

Discorsi di Mercato

Mexican Inflation Seen Easing in May -- Market Talk

8 giu 2026, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

8 giu 2026, 16:03 UTC

Acquisizioni, Fusioni, Takeovers

Orange Bought Stake From Lorca

8 giu 2026, 16:01 UTC

Acquisizioni, Fusioni, Takeovers

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 giu 2026, 16:01 UTC

Acquisizioni, Fusioni, Takeovers

Orange Acquires 100% Ownership of MasOrange

8 giu 2026, 15:58 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 giu 2026, 15:58 UTC

Discorsi di Mercato

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 giu 2026, 15:55 UTC

Discorsi di Mercato

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 giu 2026, 15:41 UTC

Discorsi di Mercato

Gold Falls Below 200-Day Moving Average -- Market Talk

Confronto tra pari

Modifica del prezzo

Compugen Ltd Previsione

Obiettivo di Prezzo

By TipRanks

138.1% in crescita

Previsioni per 12 mesi

Media 5 USD 138.1%

Alto 6 USD

Basso 4 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Compugen Ltd - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

3 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 3 che hanno fornito valutazioni azionarie a Compugen Ltd - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.